Sonnenblick, Amir <br/><br/>
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.  [electronic resource] 

 -  Oncotarget  Oct 2015 
 - 30306-16 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.5080  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Annexin A1--genetics<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--chemistry<br/>Chemotherapy, Adjuvant<br/>Databases, Genetic<br/>Disease Progression<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Finland<br/>Gene Expression Profiling--methods<br/>Gene Expression Regulation, Neoplastic<br/>Genetic Predisposition to Disease<br/>Humans<br/>Kaplan-Meier Estimate<br/>Multivariate Analysis<br/>Patient Selection<br/>Phenotype<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Protein Array Analysis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proteomics--methods<br/>Receptor, ErbB-2--analysis<br/>Reproducibility of Results<br/>Risk Factors<br/>Time Factors<br/>Trastuzumab--therapeutic use<br/>Treatment Outcome